McKesson Corporation Reports 11% Revenue Growth to $106.2 Billion in Latest Quarter

McKesson Corporation reported significant financial performance improvements in its latest quarterly filing, with revenues reaching $106.2 billion for the three months ended December 31, 2025, an increase of 11% from $95.3 billion in the same period last year. For the nine months, revenues rose 15% to $307.1 billion compared to $268.2 billion in the prior year. The company’s net income attributable to McKesson Corporation also saw a substantial increase, rising 35% to $1.2 billion for the quarter and 51% to $3.1 billion for the nine months. Diluted earnings per share increased to $9.59 for the quarter and $24.73 for the nine months, compared to $6.95 and $15.80, respectively, in the previous year.

The company noted several strategic developments during the reporting period, including the completion of two significant acquisitions. On April 1, 2025, McKesson acquired an 80% interest in PRISM Vision Holdings for $875 million, and on June 2, 2025, it acquired a 70% interest in Community Oncology Revitalization Enterprise Ventures for $2.5 billion. These acquisitions are expected to enhance McKesson's capabilities in the oncology and specialty pharmaceutical sectors. Additionally, the company announced plans to separate its Medical-Surgical Solutions segment into an independent entity, further streamlining its operations.

Operationally, McKesson reported a slight increase in total operating expenses, which remained flat at $2.1 billion for the quarter, while decreasing by 6% to $6.4 billion for the nine months. The company’s North American Pharmaceutical segment, which accounted for the majority of revenues, reported a 9% increase in revenues for the quarter, driven by higher volumes from retail national account customers. The Oncology & Multispecialty segment experienced a notable 37% revenue increase for the quarter, attributed to growth in specialty pharmaceuticals and provider solutions.

Looking ahead, McKesson anticipates continued growth driven by market expansion and the successful integration of its recent acquisitions. The company remains focused on enhancing operational efficiencies and managing costs, particularly in light of ongoing restructuring initiatives aimed at modernizing its technology service operating model. McKesson's liquidity position remains strong, with $3.1 billion in cash and cash equivalents as of December 31, 2025, and access to substantial credit facilities, positioning the company well for future investments and operational needs.